吉林大学学报(医学版) ›› 2023, Vol. 49 ›› Issue (3): 802-810.doi: 10.13481/j.1671-587X.20230333
• 综述 • 上一篇
收稿日期:
2022-08-22
出版日期:
2023-05-28
发布日期:
2023-06-28
通讯作者:
商丽华
E-mail:bjslh@sohu.com
作者简介:
王秋雨(1997-),男,河南省周口市人,在读硕士研究生,主要从事心血管疾病相关方面的研究。
基金资助:
Received:
2022-08-22
Online:
2023-05-28
Published:
2023-06-28
摘要:
肥厚型梗阻性心肌病(HOCM)是一种常见的遗传性心肌病,典型症状包括呼吸困难、胸痛、心悸和晕厥,严重者可导致死亡。HOCM患者常同时并发二尖瓣关闭不全(MI),MI对该类患者的病程及预后起重要作用。HOCM患者并发MI的治疗主要通过药物改善症状或手术消除异常的解剖结构。药物治疗是基础,但无法明确改善疾病症状和预后。对于梗阻和症状较严重的患者,外科手术切除或介入消融肥厚心肌为更好的选择,二者统称为室间隔减容术(SRT)。外科手术切除的并发症发生率更低,减弱左心室流出道梗阻作用更彻底和持久,目前仍是治疗的金标准。外科手术方法的选择也略有不同,其手术策略的制订主要取决于MI产生的病理机制。现综述近年来HOCM并发MI的机制和治疗进展,为该类患者精准治疗提供参考。
中图分类号:
王秋雨,张帅朋,徐熙若,李馨,商丽华. 肥厚型梗阻性心肌病患者并发二尖瓣关闭不全的机制及其治疗策略研究进展[J]. 吉林大学学报(医学版), 2023, 49(3): 802-810.
1 | ROBERTS R, SIGWART U. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy[J].Circulation, 2005,112(2): 293-296. |
2 | MARON M S, OLIVOTTO I, ZENOVICH A G,et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction[J]. Circulation, 2006, 114(21): 2232-2239. |
3 | BRAUNWALD E. Obstruction in hypertrophic cardiomyopathy: how often does it occur? Should it be treated? If so, how?[J]. Circulation, 2012, 126(20): 2369-2370. |
4 | CARDIM N, GALDERISI M, EDVARDSEN T,et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association[J]. Eur Heart J Cardiovasc Imaging, 2015, 16(3): 280. |
5 | ANTUNES M O, SCUDELER T L. Hypertrophic cardiomyopathy[J]. Int J Cardiol Heart Vasc, 2020, 27: 100503. |
6 | YU E H, OMRAN A S, WIGLE E D, et al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy[J]. J Am Coll Cardiol, 2000, 36(7): 2219-2225. |
7 | HENRY W L, CLARK C E, GRIFFITH J M, et al. Mechanism of left ventricular outlfow obstruction in patients with obstructive asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis)[J]. Am J Cardiol, 1975, 35(3): 337-345. |
8 | DELLING F N, SANBORN D Y, LEVINE R A,et al. Frequency and mechanism of persistent systolic anterior motion and mitral regurgitation after septal ablation in obstructive hypertrophic cardiomyopathy[J]. Am J Cardiol, 2007, 100(11): 1691-1695. |
9 | RO R, HALPERN D, SAHN D J, et al. Vector flow mapping in obstructive hypertrophic cardiomyopathy to assess the relationship of early systolic left ventricular flow and the mitral valve[J]. J Am Coll Cardiol, 2014, 64(19): 1984-1995. |
10 | SHERRID M V, GUNSBURG D Z, MOLDENHAUER S, et al. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2000, 36(4): 1344-1354. |
11 | SILBIGER J J. Abnormalities of the mitral apparatus in hypertrophic cardiomyopathy: echocardiographic, pathophysiologic, and surgical insights[J]. J Am Soc Echocardiogr, 2016, 29(7): 622-639. |
12 | TEO E P, TEOH J G, HUNG J. Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy[J]. Curr Opin Cardiol, 2015, 30(5): 475-482. |
13 | WOO A, JEDRZKIEWICZ S. The mitral valve in hypertrophic cardiomyopathy: it’s a long story[J]. Circulation, 2011, 124(1): 9-12. |
14 | SCHWAMMENTHAL E, LEVINE R A. Dynamic subaortic obstruction: a disease of the mitral valve suitable for surgical repair?[J]. J Am Coll Cardiol, 1996, 28(1): 203-206. |
15 | IBRAHIM M, RAO C, ASHRAFIAN H, et al. Modern management of systolic anterior motion of the mitral valve[J]. Eur J Cardiothorac Surg, 2012, 41(6): 1260-1270. |
16 | HENEIN M, ARVIDSSON S, PILEBRO B, et al. Long mitral valve leaflets determine left ventricular outflow tract obstruction during exercise in hypertrophic cardiomyopathy[J]. Int J Cardiol, 2016, 212: 47-53. |
17 | GILMANOV D S H, BEVILACQUA S, SOLINAS M, et al. Minimally invasive septal myectomy for the treatment of hypertrophic obstructive cardiomyopathy and intrinsic mitral valve disease[J].Innovations (Phila), 2015, 10(2): 106-113. |
18 | VESELKA J, ANAVEKAR N S, CHARRON P. Hypertrophic obstructive cardiomyopathy[J]. Lancet, 2017, 389(10075): 1253-1267. |
19 | MARON M S, ROWIN E J, WESSLER B S, et al. Enhanced American college of cardiology/American heart association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy[J].JAMA Cardiol,2019,4(7):644-657. |
20 | GERSH B J, MARON B J, BONOW R O, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2011, 124(24): 2761-2796. |
21 | OMMEN S R, MITAL S, BURKE M A, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J]. Circulation, 2020, 142(25): e558-e631. |
22 | SHERRID M V, SHETTY A, WINSON G, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil[J].Circ Heart Fail, 2013, 6(4): 694-702. |
23 | SHERRID M V, BARAC I, MCKENNA W J, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2005, 45(8): 1251-1258. |
24 | HO C Y, DAY S M, AXELSSON A, et al. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial[J]. Nat Med, 2021, 27(10): 1818-1824. |
25 | SPARROW A J, WATKINS H, DANIELS M J,et al. Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux caused by thin filament hypertrophic cardiomyopathy mutations[J]. Am J Physiol Heart Circ Physiol, 2020, 318(3): H715-H722. |
26 | HO C Y, OLIVOTTO I, JACOBY D, et al. Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy[J]. Circ Heart Fail, 2020, 13(6): e006853. |
27 | DESAI M Y, WOLSKI K, OWENS A, et al. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy[J]. Am Heart J, 2021, 239: 80-89. |
28 | VESELKA J, LIEBREGTS M, COOPER R, et al. Outcomes of patients with hypertrophic obstructive cardiomyopathy and pacemaker implanted after alcohol septal ablation[J].JACC Cardiovasc Interv,2022,15(19): 1910-1917. |
29 | ZHOU M Y, TA S J, HAHN R T, et al. Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy[J].JAMA Cardiol,2022,7(5):529-538. |
30 | LAWRENZ T, KUHN H. Endocardial radiofrequency ablation of septal hypertrophy. A new catheter-based modality of gradient reduction in hypertrophic obstructive cardiomyopathy[J]. Z Kardiol, 2004, 93(6): 493-499. |
31 | 蔡 迟, 王 靖, 楚建民, 等. 心内膜室间隔射频消融治疗肥厚型梗阻性心肌病的疗效分析[J]. 中国心脏起搏与心电生理杂志, 2021, 35(4): 325-330. |
32 | LAWRENZ T, LAWIN D, RADKE K, et al. Acute and chronic effects of endocardial radiofrequency ablation of septal hypertrophy in HOCM[J]. J Cardiovasc Electrophysiol, 2021, 32(10): 2617-2624. |
33 | 孟祥彬, 唐熠达. 经导管二尖瓣钳夹系统解除左心室流出道梗阻治疗肥厚型梗阻性心肌病的应用现状及前景[J]. 中国循环杂志, 2022, 37(3): 298-301. |
34 | MORROW A G, LAMBREW C T, BRAUNWALD E. Idiopathic hypertrophic subaortic stenosis. ii. operative treatment and the results of pre- and postoperative hemodynamic evaluations[J]. Circulation, 1964, 30: 120-151. |
35 | WANG S Y, CUI H, YU Q J, et al. Excision of anomalous muscle bundles as an important addition to extended septal myectomy for treatment of left ventricular outflow tract obstruction[J]. J Thorac Cardiovasc Surg, 2016, 152(2): 461-468. |
36 | MINAKATA K, DEARANI J A, NISHIMURA R A, et al. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae[J]. J Thorac Cardiovasc Surg, 2004, 127(2): 481-489. |
37 | OMMEN S R, MARON B J, OLIVOTTO I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2005, 46(3): 470-476. |
38 | RAFFA G M, ROMANO G, FALLETTA C, et al. Surgical management of hypertrophic obstructive cardiomyopathy: the role of mitral valve[J]. G Ital Cardiol (Rome), 2019, 20(2): 109-116. |
39 | LILLEHEI C W, LEVY M J. Transatrial exposure for correction of subaortic stenosis[J]. JAMA, 1963, 186: 8-13. |
40 | CASSELMAN F, VANERMEN H. Idiopathic hypertrophic subaortic stenosis can be treated endoscopically[J]. J Thorac Cardiovasc Surg, 2002, 124(6): 1248-1249. |
41 | C J A K, MARC G A, SMEDIRA N G,et al. Robotic trans-mitral septal myectomy and papillary muscle reorientation for HOCM combined with or without mitral valve repair: technical aspects - How we do it[J]. J Card Surg, 2020, 35(11): 3120-3124. |
42 | MA J X, LIU J, YUAN H Y, et al. Two-port thoracoscopic myectomy for hypertrophic cardiomyopathy with three-dimensional printing[J]. Ann Thorac Surg, 2021, 111(3): e165-e168. |
43 | SUN D K, SCHAFF H V, NISHIMURA R A, et al. Transapical septal myectomy for hypertrophic cardiomyopathy with midventricular obstruction[J]. Ann Thorac Surg, 2021, 111(3): 836-844. |
44 | ISLAM T M Q, DASGUPTA S, UDDIN M,et al. Midterm outcome of septal myectomy for hypertrophic obstructive cardiomyopathy (HOCM): a single-center observational study[J].Heart Surg Forum,2020,23(6): E873-E879. |
45 | HONG J H, SCHAFF H V, NISHIMURA R A, et al. Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures[J].J Am Coll Cardiol, 2016, 68(14): 1497-1504. |
46 | KAPLE R K, MURPHY R T, DIPAOLA L M, et al. Mitral valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and surgical outcomes[J]. Ann Thorac Surg, 2008,85(5):1527-1535. |
47 | HODGES K, RIVAS C G, AGUILERA J, et al. Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center[J]. J Thorac Cardiovasc Surg, 2019, 157(6): 2289-2299. |
48 | AUTHORS/TASK FORCE MEMBERS, ELLIOTT P M, ANASTASAKIS A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2014, 35(39): 2733-2779. |
49 | 唐亚捷, 宋云虎. 221例同期不处理二尖瓣的扩大心肌切除术对肥厚型梗阻性心肌病的治疗效果及远期预后分析[J]. 中国循环杂志, 2018, 33(S1): 45-46. |
50 | VAN D L C, KOFFLARD M J, VAN H L A, et al. Sustained improvement after combined anterior mitral leaflet extension and myectomy in hypertrophic obstructive cardiomyopathy[J].Circulation,2003,108(17): 2088-2092. |
51 | KOFFLARD M J, VAN HERWERDEN L A, WALDSTEIN D J, et al. Initial results of combined anterior mitral leaflet extension and myectomy in patients with obstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 1996, 28(1): 197-202. |
52 | CARPENTIER A, ADAMS D H, FILSOUFI F. Carpentier’s reconstructive valve surgery[M]. Philadelphia: Saunders, 2010: 301-306. |
53 | HAGÈGE A A, BRUNEVAL P, LEVINE R A, et al. The mitral valve in hypertrophic cardiomyopathy: old versus new concepts[J]. J Cardiovasc Transl Res, 2011, 4(6): 757-766. |
54 | BALARAM S K, SHERRID M V, DEROSE J J J R, et al. Beyond extended myectomy for hypertrophic cardiomyopathy: the resection-plication-release (RPR) repair[J]. Ann Thorac Surg, 2005, 80(1): 217-223. |
55 | BALARAM S K, ROSS R E, SHERRID M V, et al. Role of mitral valve plication in the surgical management of hypertrophic cardiomyopathy[J]. Ann Thorac Surg, 2012, 94(6): 1990-1997;discussion 1997-1998. |
56 | DELMO WALTER E M, JAVIER M F, HETZER R. Long-term outcome of simultaneous septal myectomy and anterior mitral leaflet retention plasty in hypertrophic obstructive cardiomyopathy: the Berlin experience[J]. Ann Cardiothorac Surg, 2017, 6(4): 343-352. |
57 | MUTSUGA M, NARITA Y, USUI A. A floating stitch on the anterior mitral leaflet can eliminate systolic anterior motion in hypertrophic obstructive cardiomyopathy[J]. Semin Thorac Cardiovasc Surg, 2020, 32(2): 266-268. |
58 | SHERRID M V, BALARAM S, KIM B, et al. The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context[J]. J Am Coll Cardiol, 2016, 67(15): 1846-1858. |
59 | NISHIMURA R A, SEGGEWISS H, SCHAFF H V. Hypertrophic obstructive cardiomyopathy: surgical myectomy and septal ablation[J]. Circ Res,2017,121(7): 771-783. |
60 | HE S, HOPMEYER J, LEFEBVRE X P, et al. Importance of leaflet elongation in causing systolic anterior motion of the mitral valve[J]. J Heart Valve Dis, 1997, 6(2): 149-159. |
61 | KLUES H G, MARON B J, DOLLAR A L, et al. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy[J].Circulation,1992,85(5): 1651-1660. |
62 | KLUES H G, PROSCHAN M A, DOLLAR A L,et al. Echocardiographic assessment of mitral valve size in obstructive hypertrophic cardiomyopathy. Anatomic validation from mitral valve specimen[J]. Circulation, 1993, 88(2): 548-555. |
63 | FERRAZZI P, SPIRITO P, IACOVONI A, et al. Transaortic chordal cutting: mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy[J]. J Am Coll Cardiol, 2015, 66(15): 1687-1696. |
[1] | 赵荫涛,杨莹莹,张相钦,郑璐,徐亚威,杨海波,刘源. 卵泡抑素样蛋白1对阿霉素所致小鼠急性心肌损伤的改善作用及其机制[J]. 吉林大学学报(医学版), 2023, 49(3): 565-572. |
[2] | 万朝辉,曾良,周辉. Bax抑制因子1过表达对急性心肌梗死大鼠心肌细胞凋亡的影响及其机制[J]. 吉林大学学报(医学版), 2022, 48(1): 74-81. |
[3] | 刘振,韩明磊,崔佳佳,侯永兰,徐光翠. 氯沙坦对大鼠急性心肌梗死的保护作用及其机制[J]. 吉林大学学报(医学版), 2021, 47(6): 1397-1406. |
[4] | 成颖,杨静,饶莉,薛强,胡杰,付乐,张巧月. 水蛭素联合阿托伐他汀对急性心肌梗死大鼠血管内皮功能的影响[J]. 吉林大学学报(医学版), 2021, 47(1): 139-144. |
[5] | 周岩, 金莲花, 卢娜, 韩立志. 3种体外培养方法诱导骨髓间充质干细胞向心肌细胞分化效果比较[J]. 吉林大学学报(医学版), 2020, 46(01): 66-72. |
[6] | 万琦, 余宝刚. miR-125b对大鼠心肌梗死后心室重构的调控作用[J]. 吉林大学学报(医学版), 2020, 46(01): 84-89. |
[7] | 徐小燕, 宋子凯, 张洋, 秦玲. 急性心肌梗死急诊行PCI术后患者血清氨基末端脑钠肽前体和脂蛋白a水平变化及其临床意义[J]. 吉林大学学报(医学版), 2020, 46(01): 132-137. |
[8] | 王丽萍, 王建辉, 李树民, 杨秀红. N-乙酰半胱氨酸通路对AGT-REN双转基因高血压小鼠心肌成纤维细胞中电导钙激活钾离子通道蛋白表达的影响及其意义[J]. 吉林大学学报(医学版), 2017, 43(05): 881-886. |
[9] | 伊雪, 邬鹏宇, 杨述亮, 韩燕, 杨学慧, 张树波, 徐涛, 高毅哲, 高木火, 李占清. PI3K/Akt信号通路介导莱菔硫烷预处理对大鼠供心冷缺血再灌注损伤的影响[J]. 吉林大学学报(医学版), 2017, 43(05): 918-922. |
[10] | 赵丽晶, 康晶, 安英, 徐博, 王艳春. 鸢尾黄素对大鼠心肌纤维化的作用及其机制[J]. 吉林大学学报(医学版), 2017, 43(02): 288-292. |
[11] | 陈 玲,金 楠,李 革. 血管紧张素原基因M235T多态性与肥厚型心肌病关系的Meta分析[J]. 吉林大学学报(医学版), 2014, 40(01): 132-136. |
[12] | 刘 伟,陈 韬,韩洪波,朱 昆,马铭泽,王丹萍,高海成,金明玉. 银杏叶提取物对STZ和ISO协同诱发大鼠糖尿病心肌病的治疗作用[J]. 吉林大学学报(医学版), 2013, 39(3): 503-506. |
[13] | 张强,杨丽红,李涵 . 丹酚酸B对心肌梗死模型大鼠心肌的保护作用及其分子机制[J]. 吉林大学学报(医学版), 2013, 39(2): 268-272. |
[14] | 吕祥威|徐彤彤|秦小虎. 瘦素预处理对心肌缺血再灌注损伤小鼠血清IL-6和TNF-α表达的影响[J]. J4, 2012, 38(1): 58-61. |
[15] | 贾春澍|陈爱军|李敏|李相军|苗春生|李希宁|任立群. 硒和维生素E对克山病病区粮喂饲大鼠心肌纤维化的影响[J]. J4, 2011, 37(2): 211-214. |
|